Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.
Minaris グローバルリーダーシップチームメンバーの任命について 本日、2025年1月付けでMinarisはDr. Eytan AbrahamをChief Technology and Commercial Officerに、Darwin RichardsonをChief Operating Officerに、坂東博人博士をPresident of Japan。 Dr. Eytan Abrahamは、20年以上にわたる国際的な細胞・遺伝子治療領域の経験を有し、直近ではNational Resilience社で細胞・遺伝子・核酸治療担当副社長を務めました。Lonza GroupAGでは、研究開発部門長、細胞・遺伝子治療部門長を歴任し、細胞療法を市場に送り出しました。それ以前は、Pluristem Therapeutics ...
Allendale, NJ - Minaris announced today the appointments of Dr. Eytan Abraham as Chief Commercial and Technology Officer, Darwin Richardson as Chief Operating Officer, and Dr. Hiroto Bando as President of Japan. Dr. Abraham has more than 20 years of international cell and gene therapy experience and most recently served as Vice President, Business Head of Cell, Gene, and Nucleic Acids at National ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. January 6, 2025. 2025年1月6日 Minaris Regeneraive Medicine株式会社 代表取締役社長 坂東 博人 レゾナックからAltarisへのMinaris株式譲渡完了について Altaris, LLC（以下 Altarisという）は2025年1月6日に株式会社レゾナック・ホールディングス（以下「レゾナック」という）の子会社であるMinaris Regenerative Medicine （米国のMinaris Regenerative Medicine, LLC、日本のMinaris Regenerative Medicine株式会社、ドイツのMinaris Regenerative Medicine ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. January 6, 2025 Altaris, LLC (collectively with its managed funds, “Altaris”) announced today that it completed the acquisition of Minaris Regenerative Medicine (Minaris Regenerative Medicine, LLC in the United States, Minaris Regenerative Medicine Co., Ltd. in Japan, Minaris Regenerative Medicine GmbH in Germany, and along with ...
Allendale, NJ, USA and Taipei, Taiwan – October 2, 2024 Minaris Regenerative Medicine, LLC (Minaris) and TFBS Bioscience Inc. (TFBS) are pleased to announce a strategic partnership in cell and gene therapy (CGT) mainly in North America. This collaboration is designed to enhance their capabilities to drive industry innovation by providing the one-stop-shop solutions. The strategic partnership ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024. 2024年9月24日 Minaris Regeneraive Medicine株式会社 代表取締役社長 坂東 博人 Minarisグループに関する株式譲渡契約締結について 本日2024年9月24日付にて株式会社レゾナック・ホールディングスの連結子会社である株式会社レゾナックは、Minaris Regenerative Medicine株式会社、Minaris Regenerative Medicine, LLC（アメリカ）、及びMinaris Regenerative Medicine GmbH（ドイツ）（以下、3社を総称してMinarisグループ、取締役兼CEO坂東 ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024. Minaris Regenerative Medicine (“Minaris”), a leading cell therapy contract development and manufacturing organization, is pleased to announce that its parent company, Resonac Corporation (“Resonac”), has entered into a definitive agreement to sell Minaris to a fund managed by Altaris, LLC (collectively with its ...
Yokohama, Japan, München, Deutschland und Allendale, New Jersey, USA. 24. September 2024. Minaris Regenerative Medicine (Minaris), ein führendes Auftragsentwicklungs- und Herstellungsunternehmen (CDMO) für Zelltherapien, freut sich bekanntzugeben, dass seine Mutterfirma, Resonac Corporation („Resonac“), eine endgültige Vereinbarung abgeschlossen hat über den Verkauf von Minaris an einen Fond, der ...
Yokohama, Japan - September 12th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. has been selected for the project publicly solicited by the Japanese organization New Energy and Industrial Technology Development Organization (NEDO). Details in Japanese for local news in Japan. ...